22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
18:50 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

3-V reports Phase I data for NASH candidate

3-V Biosciences Inc. (Menlo Park, Calif.) reported data from a Phase I trial in 20 healthy volunteers with a BMI of >26 and characteristics of metabolic syndrome showing that a once-daily 50 mg dose of...
07:00 , Aug 15, 2016 |  BioCentury  |  Finance

Serving returns

China's Ally Bridge Group hit the investment world's radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that...
23:44 , Apr 22, 2016 |  BC Extra  |  Company News

Management tracks

Oncology company FLX Bio Inc. (South San Francisco, Calif.) hired Rekha Hemrajani as COO. She was CFO and SVP of business and financial operations at 3-V Biosciences Inc. (Menlo Park, Calif.). Dermatology company Cipher Pharmaceuticals...
01:27 , Oct 20, 2015 |  BC Extra  |  Company News

Parsey returns to Genentech

The Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) hired Merdad Parsey as SVP of early clinical development. Parsey was Genentech's senior group medical director in its Genentech Research and Early Development unit until 2010. He left...
07:00 , Sep 21, 2015 |  BioCentury  |  Finance

Hedging in Asia

Ally Bridge Group expects its newest investment vehicle - an Asia-focused healthcare hedge fund - will have a surplus of buying opportunities given the plunge of the stock market in China. In other territories, such...
01:42 , Feb 21, 2015 |  BC Extra  |  Company News

Management tracks

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) promoted Lisa Bright to chief commercial and corporate affairs officer. Bright joined Intercept last year as SVP and head of Europe. She previously held several positions at Gilead Sciences Inc. (NASDAQ:GILD),...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Financial News

3-V Biosciences completes venture financing

3-V Biosciences Inc. , Menlo Park, Calif.   Business: Cancer, Infectious   Date completed: 2014-12-30   Type: Venture financing   Raised: $28.5 million   Investors: New Enterprise Associates; Kleiner Perkins Caufield & Byers ; Rock...
00:24 , Jan 1, 2015 |  BC Extra  |  Financial News

3-V Biosciences raises $28.5M series D

3-V Biosciences Inc. (Menlo Park, Calif.) raised $28.5 million in a series D round co-led by New Enterprise Associates; Kleiner Perkins Caufield & Byers ; and Rock Springs Capital Management. Ally Bridge Group and other...